A global, phase III clinical trial evaluating the safety and efficacy of TAVT-45 (abiraterone acetate) granules for oral suspension, an investigational enhanced formulation of abiraterone acetate for the treatment of metastatic prostate cancer, produced positive topline results.
The Decipher Prostate Genomic Classifier predicts which patients with metastatic cancer are likely to benefit from treatment intensification with the chemotherapy docetaxel and which are not likely to benefit and can therefore avoid unnecessary toxicity, according to findings by University College London and Veracyte, Inc., a genomic diagnostic company.
